News
IDYA
36.74
+1.24%
0.45
IDEAYA Biosciences grants inducement stock options for 98,000 shares at $36.29 each
PUBT · 13h ago
IDEAYA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 13h ago
Press Release: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 13h ago
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 13h ago
IDEAYA Biosciences (IDYA) First Patient Enrollment Puts Valuation Back In Focus
Simply Wall St · 1d ago
IDEAYA Biosciences Shareholders Back Leadership, Governance Changes
TipRanks · 3d ago
IDEAYA Biosciences shareholders ratified PwC as auditor for 2026
PUBT · 3d ago
IDEAYA Biosciences (IDYA) Is Up 13.2% After New MTAP Trial And Roche Collaboration - Has The Bull Case Changed?
Simply Wall St · 4d ago
Weekly Report: what happened at IDYA last week (0615-0619)?
Weekly Report · 4d ago
Ideaya Advances IDE034 Into First-in-Human Trial for Advanced Solid Tumors
TipRanks · 06/18 16:34
IDEAYA's Board Of Directors Elect Hata As Chairman Of Board
NASDAQ · 06/17 12:39
Ideaya Biosciences elects CEO Yujiro Hata as chairman
TipRanks · 06/17 10:35
IDEAYA Biosciences names CEO Yujiro S. Hata as board chairman
PUBT · 06/17 10:00
IDEAYA BIOSCIENCES - TERRY ROSEN TO SERVE AS LEAD INDEPENDENT DIRECTOR
Reuters · 06/17 10:00
IDEAYA BIOSCIENCES ANNOUNCES YUJIRO S. HATA ELECTED CHAIRMAN OF ITS BOARD OF DIRECTORS
Reuters · 06/17 10:00
*IDEAYA Biosciences: Yujiro S. Hata Elected Chmn of Bd of Directors>IDYA
Dow Jones · 06/17 10:00
Press Release: IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
Dow Jones · 06/17 10:00
IDEAYA Biosciences (IDYA) Stock Could Be 81.5% Below Fair Value After Trial Milestone
Simply Wall St · 06/17 05:26
Analysts Offer Insights on Healthcare Companies: Cadrenal Therapeutics, Inc. (CVKD) and IDEAYA Biosciences (IDYA)
TipRanks · 06/16 13:10
Is IDEAYA Biosciences (IDYA) Quietly Reframing Its MTAP Strategy With the New IDE892 Combinations?
Simply Wall St · 06/15 21:23
More
Webull provides a variety of real-time IDYA stock news. You can receive the latest news about Ideaya Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.